Prothena Co. plc (NASDAQ:PRTA - Get Free Report)'s stock price reached a new 52-week low during trading on Wednesday . The company traded as low as $23.41 and last traded at $23.65, with a volume of 8928 shares. The stock had previously closed at $23.95.
Wall Street Analyst Weigh In
PRTA has been the topic of several research reports. JMP Securities upped their price objective on shares of Prothena from $81.00 to $85.00 and gave the company a "market outperform" rating in a report on Friday, February 16th. Deutsche Bank Aktiengesellschaft assumed coverage on Prothena in a report on Tuesday, December 12th. They issued a "buy" rating and a $62.00 price target on the stock. Bank of America reissued a "neutral" rating and issued a $38.00 price objective (down previously from $68.00) on shares of Prothena in a research note on Tuesday, January 30th. Oppenheimer lowered their target price on Prothena from $98.00 to $80.00 and set an "outperform" rating on the stock in a research report on Tuesday, February 20th. Finally, Royal Bank of Canada reduced their price target on shares of Prothena from $36.00 to $35.00 and set a "sector perform" rating for the company in a research report on Friday, February 16th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $69.63.
View Our Latest Stock Report on Prothena
Prothena Price Performance
The firm has a market cap of $1.30 billion, a P/E ratio of -8.66 and a beta of 0.21. The company has a fifty day moving average of $27.45 and a 200-day moving average of $35.03.
Prothena (NASDAQ:PRTA - Get Free Report) last posted its earnings results on Thursday, February 15th. The biotechnology company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.03). The firm had revenue of $0.32 million for the quarter, compared to the consensus estimate of $2.15 million. Prothena had a negative return on equity of 24.84% and a negative net margin of 160.91%. Prothena's quarterly revenue was down 99.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.12 EPS. On average, sell-side analysts expect that Prothena Co. plc will post -4.87 EPS for the current fiscal year.
Insider Activity at Prothena
In related news, CAO Karin L. Walker sold 5,000 shares of Prothena stock in a transaction that occurred on Wednesday, January 24th. The shares were sold at an average price of $34.00, for a total value of $170,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 28.20% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the stock. KBC Group NV purchased a new position in shares of Prothena during the 4th quarter valued at $34,000. West Tower Group LLC bought a new position in Prothena in the 2nd quarter worth about $45,000. Point72 Middle East FZE purchased a new stake in shares of Prothena in the 4th quarter valued at about $48,000. PNC Financial Services Group Inc. boosted its position in shares of Prothena by 265.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 1,544 shares of the biotechnology company's stock valued at $56,000 after acquiring an additional 1,122 shares during the last quarter. Finally, Lazard Asset Management LLC grew its holdings in shares of Prothena by 61.1% during the first quarter. Lazard Asset Management LLC now owns 1,733 shares of the biotechnology company's stock worth $63,000 after purchasing an additional 657 shares in the last quarter. Hedge funds and other institutional investors own 97.08% of the company's stock.
About Prothena
(
Get Free Report)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Featured Articles
Before you consider Prothena, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prothena wasn't on the list.
While Prothena currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.
Get This Free Report
